Thomas Jefferson University

Paul F Bray

Michael Holinstat

Leonard Edelstein

A substance of Formula (I) for use as a medicament for the treatment of cardiovascular diseases, wherein R is nitrogen or carbon; Ris selected from the group consisting of a hydrogen, a trifluoromethyl, a methyloxyphenyl, a phenyl, a C-Cphenylalkyl, a halogenated phenyl, a halogenated C-Cphenylalkyl, a trifluoromethyloxy, a trifluoromethyl oxyphenyl, and a C-Cpyridinylalkyl; Ris selected from the group consisting of a C-Calkyl alcohol optionally substituted with a C-Calkoxyphenyl, a C-CN-alkylmethanamine, a C-Calkoxymethyl, a C-Cphenylalkoxymethyl, a C-Ccyclopropylalkoxymethyl, and a methoxyethoxymethyl; and Ris a phenyl or a methoxypyridinyl; and Ris selected from the group consisting of a hydrogen, a cyano, a C-Csulfonyl, a nitro, and a trifluoromethyl. 

Non-selective protease activated receptor 4 ALA120THR isoform antagonist

Disclosed herein are methods for determining whether a PAR4 inhibitor should be administered to a human subject, the methods comprising administering a PAR4 inhibitor to a subject determined to have a 'G' allele for a single-nucleotide polymorphism (SNP) at rs773902, and not administering a PAR4 inhibitor to a subject determined to have an 'A' allele for the SNP at rs773902. A genotyping assay can be used to determine the SNP.

PAR4 inhibitor therapy for patients with PAR4 polymorphism

The present disclosure relates to methods of affecting platelet activation by the use of a PC-TP inhibitor. The PC-TP inhibitor can be administered to a subject in need thereof in order to prevent or treat pathologic thrombosis, or to treat a disorder treatable by a PAR4 inhibitor.

Growing community of inventors

Penn Valley, PA, United States of America

Paul F Bray